2018 Q1 Form 10-Q Financial Statement
#000156459018009416 Filed on April 27, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| Revenue | $373.4M | $303.7M |
| YoY Change | 22.95% | 28.31% |
| Cost Of Revenue | $82.33M | $50.01M |
| YoY Change | 64.65% | 15.97% |
| Gross Profit | $291.1M | $253.7M |
| YoY Change | 14.73% | 31.05% |
| Gross Profit Margin | 77.95% | 83.54% |
| Selling, General & Admin | $138.3M | $120.0M |
| YoY Change | 15.26% | 13.98% |
| % of Gross Profit | 47.52% | 47.3% |
| Research & Development | $183.9M | $145.0M |
| YoY Change | 26.86% | -8.68% |
| % of Gross Profit | 63.19% | 57.15% |
| Depreciation & Amortization | $23.63M | $19.41M |
| YoY Change | 21.74% | 3.66% |
| % of Gross Profit | 8.12% | 7.65% |
| Operating Expenses | $322.3M | $265.0M |
| YoY Change | 21.61% | 0.35% |
| Operating Profit | -$44.37M | -$20.21M |
| YoY Change | 119.58% | -75.03% |
| Interest Expense | $11.56M | $10.12M |
| YoY Change | 14.26% | 2.8% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$200.0K | $3.500M |
| YoY Change | -105.71% | 1650.0% |
| Pretax Income | -$50.80M | -$24.31M |
| YoY Change | 109.02% | -72.73% |
| Income Tax | -$6.655M | -$8.016M |
| % Of Pretax Income | ||
| Net Earnings | -$44.15M | -$16.29M |
| YoY Change | 171.02% | -80.39% |
| Net Earnings / Revenue | -11.82% | -5.36% |
| Basic Earnings Per Share | -$0.25 | |
| Diluted Earnings Per Share | -$0.26 | -$94.38K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 175.9M | 172.9M |
| Diluted Shares Outstanding | 176.2M |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.383B | $678.1M |
| YoY Change | 103.92% | 48.41% |
| Cash & Equivalents | $474.0M | $348.2M |
| Short-Term Investments | $908.8M | $329.8M |
| Other Short-Term Assets | $71.80M | $60.30M |
| YoY Change | 19.07% | 3.61% |
| Inventory | $468.2M | $384.1M |
| Prepaid Expenses | ||
| Receivables | $318.4M | $230.3M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $2.241B | $1.353B |
| YoY Change | 65.66% | 36.26% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $895.4M | $824.0M |
| YoY Change | 8.67% | 13.64% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $313.6M | $533.6M |
| YoY Change | -41.23% | 69.72% |
| Other Assets | $439.7M | $485.0M |
| YoY Change | -9.34% | 86.18% |
| Total Long-Term Assets | $2.356B | $2.586B |
| YoY Change | -8.9% | -3.31% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $2.241B | $1.353B |
| Total Long-Term Assets | $2.356B | $2.586B |
| Total Assets | $4.597B | $3.939B |
| YoY Change | 16.71% | 7.41% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $163.5M | $146.6M |
| YoY Change | 11.53% | 0.48% |
| Accrued Expenses | $131.5M | $110.8M |
| YoY Change | 18.68% | -0.45% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $365.3M | $22.50M |
| YoY Change | 1523.56% | |
| Total Short-Term Liabilities | $773.5M | $340.2M |
| YoY Change | 127.37% | -12.32% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $817.7M | $668.4M |
| YoY Change | 22.34% | 0.06% |
| Other Long-Term Liabilities | $198.6M | $160.9M |
| YoY Change | 23.43% | -9.2% |
| Total Long-Term Liabilities | $1.016B | $829.3M |
| YoY Change | 22.55% | -1.88% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $773.5M | $340.2M |
| Total Long-Term Liabilities | $1.016B | $829.3M |
| Total Liabilities | $1.790B | $1.170B |
| YoY Change | 53.03% | -15.06% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $2.809B | $2.769B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $4.597B | $3.939B |
| YoY Change | 16.71% | 7.41% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$44.15M | -$16.29M |
| YoY Change | 171.02% | -80.39% |
| Depreciation, Depletion And Amortization | $23.63M | $19.41M |
| YoY Change | 21.74% | 3.66% |
| Cash From Operating Activities | -$42.51M | -$80.40M |
| YoY Change | -47.13% | -53.12% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $30.16M | $69.09M |
| YoY Change | -56.34% | 52.84% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $99.00K | $1.391M |
| YoY Change | -92.88% | 827.33% |
| Cash From Investing Activities | -$71.73M | $25.00M |
| YoY Change | -386.94% | -67.53% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -9.765M | -6.700M |
| YoY Change | 45.75% | -82.04% |
| NET CHANGE | ||
| Cash From Operating Activities | -42.51M | -80.40M |
| Cash From Investing Activities | -71.73M | 25.00M |
| Cash From Financing Activities | -9.765M | -6.700M |
| Net Change In Cash | -124.0M | -62.10M |
| YoY Change | 99.69% | -52.88% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$42.51M | -$80.40M |
| Capital Expenditures | $30.16M | $69.09M |
| Free Cash Flow | -$72.67M | -$149.5M |
| YoY Change | -51.39% | -31.02% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
7755000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
207000 | |
| CY2017Q4 | bmrn |
Stockholders Equity Adjusted Balance
StockholdersEquityAdjustedBalance
|
2828711000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-4998000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
36997000 | |
| CY2017Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
19412000 | |
| CY2018Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
8601000 | |
| CY2018Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
4348000 | |
| CY2017Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1555000 | |
| CY2018Q1 | us-gaap |
Revenues
Revenues
|
373447000 | |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
303745000 | |
| CY2018Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
82333000 | |
| CY2018Q1 | bmrn |
Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency
StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency
|
-9765000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
30674000 | |
| CY2017Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
2043000 | |
| CY2017Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-660000 | |
| CY2018Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
22899000 | |
| CY2018Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
0 | |
| CY2017Q1 | us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
1894000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-9765000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-6743000 | |
| CY2018Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-40000 | |
| CY2018Q1 | us-gaap |
Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
|
0 | |
| CY2017Q1 | us-gaap |
Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
|
3252000 | |
| CY2018Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-13988000 | |
| CY2017Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-10441000 | |
| CY2017Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
1730000 | |
| CY2017Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
1353000 | |
| CY2017Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-969000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
14051000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
22660000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-2763000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
527000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-77822000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
2744000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-80443000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
69090000 | |
| CY2017Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
149916000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
145933000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
54388000 | |
| CY2018Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
99000 | |
| CY2017Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
1391000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-71734000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
13134000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-124048000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-60096000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
408330000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
348234000 | |
| CY2018Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
11731000 | |
| CY2017Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
6376000 | |
| CY2018Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1528000 | |
| CY2017Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | |
| CY2018Q1 | bmrn |
Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
|
-11367000 | |
| CY2017Q1 | bmrn |
Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
|
-26297000 | |
| CY2018Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(1) NATURE OF OPERATIONS</p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s therapy portfolio consists of six commercial products and multiple clinical and pre-clinical product candidates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. </p></div> | |
| CY2018Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(2) BASIS OF PRESENTATION</p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective method as discussed in Note 3 - <font style="font-style:italic;">Significant Accounting Policies</font>. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of Accumulated Deficit. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2018 or any other period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</p></div> | |
| CY2018Q1 | us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Product Revenues </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In the U.S., the Company’s commercial products are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Outside the U.S., the Company’s commercial products are sold to its authorized distributors or directly to government purchasers or hospitals, which act as the end-users. Revenues from product sales are recognized when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment to the customer. Amounts collected from customers and remitted to governmental authorities, which primarily consist of value-added taxes related to product sales in foreign jurisdictions, are presented on a net basis in the Company’s Condensed Consolidated Statements of Comprehensive Loss, in that taxes billed to customers are not included as a component of Net Product Revenues. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Aldurazyme revenues, the Company receives a payment ranging from 39.5% to 50% on worldwide net Aldurazyme sales by Genzyme Corporation (Genzyme) depending on sales volume, which is included in Net Product Revenues in the Company’s Condensed Consolidated Statements of Comprehensive Loss. Under the previous guidance the Company only recognized a portion of this amount as product transfer revenue when the product was released to Genzyme because all of the Company’s performance obligations were fulfilled at that point, the prices were substantially fixed or determinable and title to, and risk of loss for, the product had transferred to Genzyme. The product transfer revenue only represented the fixed amount per unit of Aldurazyme that Genzyme was required to pay the Company if the product was unsold by Genzyme. The amount of product transfer revenue was eventually deducted from the calculated royalty recognized when the product was subsequently sold by Genzyme. The Company recorded the Aldurazyme revenues based on net sales information provided by Genzyme and recorded product transfer revenues based on the fulfillment of Genzyme purchase orders in accordance with the terms of the related agreements with Genzyme. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company recognizes its best estimate of the entire revenue that it expects to receive when the product is released and control is transferred to Genzyme. The Company records Aldurazyme net product revenues based on the estimated variable consideration payable when the product is sold through by Genzyme. Actual amounts of consideration ultimately received may differ from the Company’s estimates, however the Company does not expect any such amounts to be material. If actual results in the future vary from the Company’s estimates, the Company will make adjustments, which would affect Net Product Revenues and earnings in the period such variances become known. </p></div> | |
| CY2018Q1 | bmrn |
Number Of Products Approved
NumberOfProductsApproved
|
6 | |
| CY2018Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-44149000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-16290000 | |
| CY2018Q1 | us-gaap |
Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
|
1322000 | |
| CY2017Q1 | us-gaap |
Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
|
0 | |
| CY2018Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-45471000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-16290000 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
218000 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
0 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
24568000 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22027000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
1702708000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
260000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
6574000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
1696394000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
908815000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
313599000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
1786045000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
4592000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
1781753000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
797940000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
385785000 | |
| CY2018Q1 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
303298000 | |
| CY2018Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
326359000 | |
| CY2018Q1 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
629657000 | |
| CY2018Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
119755000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1303434000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
406734000 | |
| CY2018Q1 | bmrn |
Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
|
4000000 | |
| CY2018Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
52642000 | |
| CY2018Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
194581000 | |
| CY2018Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
220938000 | |
| CY2018Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
16496000 | |
| CY2017Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
18820000 | |
| CY2018Q1 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
10221000 | |
| CY2017Q4 | us-gaap |
Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
|
9740000 | |
| CY2018Q1 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
20623000 | |
| CY2017Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
14464000 | |
| CY2017Q4 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
5528000 | |
| CY2017Q4 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
9500000 | |
| CY2018Q1 | us-gaap |
Convertible Debt
ConvertibleDebt
|
1182998000 | |
| CY2017Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
1174470000 | |
| CY2018Q1 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
1263313000 | |
| CY2017Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
1344319000 | |
| CY2018Q1 | us-gaap |
Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
|
11658000 | |
| CY2018Q1 | us-gaap |
Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
|
35488000 | |
| CY2017Q4 | us-gaap |
Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
|
9663000 | |
| CY2017Q1 | us-gaap |
Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
|
-2633000 | |
| CY2017Q1 | us-gaap |
Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
|
5768000 | |
| CY2018Q1 | us-gaap |
Asset Retirement Obligation
AssetRetirementObligation
|
4300000 | |
| CY2017Q4 | us-gaap |
Asset Retirement Obligation
AssetRetirementObligation
|
4200000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
36608000 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
30674000 | |
| CY2018Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
3500000 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
3200000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
766810 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
33.34 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | |
| CY2018Q1 | us-gaap |
Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
|
-11246000 | |
| CY2018Q1 | us-gaap |
Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
|
-5785000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
|
-463000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-4998000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
|
-605000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-7796000 | |
| CY2018Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2018Q1 | bmrn |
Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
|
613800000 | |
| CY2018Q1 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
199200000 | |
| CY2018Q1 | us-gaap |
Purchase Obligation
PurchaseObligation
|
53200000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | |
| CY2018Q1 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2018Q1 | bmrn |
Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
|
-4600000 |
